Experimental antibody drug tested for Tough-to-Treat leukemia
NCT ID NCT03698552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called ADCT-602 in 37 people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that had returned or stopped responding to other treatments. The drug is a lab-made antibody that targets a protein (CD22) on cancer cells to stop them from growing. The study was stopped early, but it aimed to find the safest dose and see if the drug could shrink or eliminate the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTS 5 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer
Monrovia, California, 91016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- Engineered immune cells take aim at tough childhood leukemia
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- New drug cocktail shows promise for Hard-to-Treat leukemia
- Can a pill make CAR T-Cell therapy last longer?
- New drug combo shows promise for tough leukemia cases